Breaking News

AREVA Med Launches New Production Facility

November 22, 2013

Will produce lead-212 for Phase I trial

AREVA Med has launched its Maurice Tubiana facility located at Bessines-sur-Gartempe, France, following administrative authorizations and completing technical testing. The facility began production to extract and purify lead-212 for medical use.
 
Lead-212 is a rare metal used in the development of treatments for certain cancers that do not respond to other conventional methods. Nuclear medicine is dependent on the availability of high purity isotopes and the production at the Maurice Tubiana facility will provide sufficient amounts of high-purity lead 212 for clinical development. Lead-212 is currently being used in an AREVA Med Phase I trial at the University of Alabama at Birmingham.
 
Patrick Bourdet, chief executive officer of AREVA Med, said, "This facility, completed thanks to AREVA's expertise in radiochemistry and nuclear facility design and the support of our partners, confirms AREVA Med's industrial development. This will allow us to accelerate the development of alpha radio-immunotherapy using lead-212."
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.